The signaling landscape that accompanies Ephexin3 in various cancer types included the tyrosine kinase receptor <i>MET</i> and the tyrosine phosphatase receptor <i>PTPRF</i>, the serine/threonine kinases <i>MARK2</i> and <i>PAK6</i>, the Rho GTPases <i>RHOD</i>, <i>RHOF</i> and <i>RAC1</i>, and the cytoskeletal regulator <i>DIAHP1</i>. This evidence concerns the gene MARK2 and cancer.